Loading stock…

Kymera Therapeutics, Inc. (KYMR) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Kymera Therapeutics, Inc.

KYMRMarket cap $9.01BPrice $108.3

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops drugs that destroy disease-causing proteins instead of just blocking them, using a technique called targeted protein degradation. This approach could treat diseases once considered "undruggable," putting Kymera at the frontier of a whole new pharmaceutical category.

In Bastion Portfolios?

52W Return+81%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-6%2

Revenue Forecast

Rev CAGR (1y)+154%10

Rev CAGR (3y)+4%3

Rev CAGR (5y)+52%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-330%1

Net Income Margin-285%1

Free Cash Flow Margin-227%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-24%1

ROA-22%1

Earnings Stabilityna–

GEAR+VERY WEAK4

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV6.03

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-2.6%2

Dividend Yieldna–

Momentum

Short term

1 month return-7%4

3 month return-5%5

YTD return+39%9

Mid term

Price vs 52wHigh83%6

1 year return+92%10

Long term

3 year return+628%10

5 year return+95%7

Risk Shield

Price Risk

Beta1.81

Volatility58%2

Free Cash Flow

Free Cash Flow Margin-227%1

Free Cash Flow Yield-2.6%2

Quality

ROCE-26%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

KYMRKymera Therapeutics

Revenue FY25$39M

GROWTH RATING↗

AVERAGE49 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-6%2

Revenue, next 1Y+154%10

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+52%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue is set to grow 4%/yr over the next 3 years, ahead of most of the market.8/10

The runway holds up: revenue is set to grow 52%/yr over five years.10/10

WATCH

A mid-pack grower, ahead of 49% of companies worldwide.

After shrinking over the last 3 years, revenue is set to grow 4%/yr from here.

WEAKNESSES

Revenue fell 6%/yr over the last 3 years, behind 80% of companies worldwide.2/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A middle-of-the-pack grower that's turning around. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG72 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-7%4

3-month return-5%5

YTD return+39%9

MID & LONG-TERM▾SCORE

% of 52-week high83%6

1-year return+92%10

3-year return+628%10

5-year return+95%7

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +628% over three years and +95% over five, ahead of 80% of the market.

It's up 92% over the past year, but 17% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+39%).

WATCH

Returns sit at the market level over the past month (-7%) and over three months (-5%).

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout.

04Value

Are you paying a fair price for it?

Stop guessing on Kymera Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

KYMRKymera Therapeutics

Revenue FY25$39M

GROWTH RATING↗

AVERAGE49 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-6%2

Revenue, next 1Y+154%10

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+52%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue is set to grow 4%/yr over the next 3 years, ahead of most of the market.8/10

The runway holds up: revenue is set to grow 52%/yr over five years.10/10

WATCH

A mid-pack grower, ahead of 49% of companies worldwide.

After shrinking over the last 3 years, revenue is set to grow 4%/yr from here.

WEAKNESSES

Revenue fell 6%/yr over the last 3 years, behind 80% of companies worldwide.2/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A middle-of-the-pack grower that's turning around. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG72 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-7%4

3-month return-5%5

YTD return+39%9

MID & LONG-TERM▾SCORE

% of 52-week high83%6

1-year return+92%10

3-year return+628%10

5-year return+95%7

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +628% over three years and +95% over five, ahead of 80% of the market.

It's up 92% over the past year, but 17% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+39%).

WATCH

Returns sit at the market level over the past month (-7%) and over three months (-5%).

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout.

04Value

Are you paying a fair price for it?

Stop guessing on Kymera Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community